SCHEMBL2227664

SCHEMBL2227664

N#Cc1ccc(/C=C/Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.52
ALDH1A1 P00352 4/20 0.50
LMNA P02545 2/20 0.50
MAPT P10636 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP2A6 P11509 1/20 0.48
TSHR P16473 1/20 0.46
HDAC2 Q92769 2/20 0.46
P4HB P07237 1/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 1/20 0.44
SNCA P37840 1/20 0.44
NR1H3 Q13133 1/20 0.42
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA6 P23280 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2227670 1.00 FBP1 (0.52) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL1260529 0.85 FBP1 (0.59) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL21574805 0.85 FBP1 (0.59) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL1687911 0.85 FBP1 (0.59) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL13799049 0.85 FBP1 (0.59) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL1687898 0.85 FBP1 (0.59) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL8699093 0.85 FBP1 (0.59) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL22448685 0.81 FBP1 (0.52) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL700236 0.81 ALDH1A1 (0.59) FBP1ALDH1A1LMNAMAPTL3MBTL1
SCHEMBL11486259 0.81 ALDH1A1 (0.59) FBP1ALDH1A1LMNAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113511972-B (E) Process for preparing (E) -4-aryl-2, 2-difluoro-3-butenoic acid derivatives 昆明理工大学 2025-01-21 CN disclosed
WO-2023160035-A1 β-ELEMENE VINYLATION COUPLED DERIVATIVE, AND PREPARATION THEREOF AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG 杭州师范大学 2023-08-31 WO disclosed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP disclosed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK FBP1 2246/4885ALDH1A1 2367/4885LMNA 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.